Help us find the next major breakthrough in stroke treatment

I want to donate

Donation

£

The next major breakthrough in stroke treatment could be right around the corner. Will you give a gift today so we can find it and unlock its potential?

 

Stroke is the second biggest killer in the world. Every year there are around 152,000 strokes in the UK and, tragically, more than around 40,000 die from a stroke each year. This is why there is an urgent need to find new and effective treatments for stroke.

 

Kind donations from supporters like you are enabling Professor Pippa Tyrrell and her team to continue Phase 2 trials of IL-1Ra, a drug which is one of the most promising new developments in stroke research. If the next round of testing is successful, it could reveal IL-1Ra to be a possible major treatment for stroke.

 

One of the reasons Professor Tyrrell is so excited about IL-1Ra is that it could be suitable for almost everybody - not just for a small percentage of stroke survivors like thrombolysis with clot-busting drugs. It could help people whether they are 19 or 90, and no matter what type of stroke they've had.

 

Professor Pippa Tyrell, Professor of Stroke Medicine and Honorary Stroke Consultant, said: ''The potential of IL-1Ra is one of the most exciting developments in stroke treatment that I have seen in a long time. So it's wonderful to have your support at this pivotal point in our history. Please will you give a gift today to help fund the next big breakthrough in stroke research?'' 

 

It has been known for many years that IL-1Ra is a safe treatment for rheumatoid arthritis. For these people the drug works by reducing inflammation in their joints. Now, a study has proved that IL-1Ra can reduce inflammation in the brain too after stroke. The sooner we can reduce inflammation after a stroke, the more we can minimise mobility problems, speech difficulties, memory loss and more.

 

As you read this, Phase 2 IL-1Ra trials are already well advanced. Professor Tyrrell and her team have finished testing the drug on a small group of people who have had one type of haemorragic stroke, caused by bleeding in and around the brain, and the preliminary results look very positive.

 

If Professor Tyrrell and her team can prove the effectiveness of IL-1Ra, then they will have the knowledge they need to move on to Phase 3, which will be full scale national trials. Beyond Phase 3, if proven effective, IL-1Ra could be administered in hospitals up and down the country.